IDH2: A novel biomarker for environmental exposure in blood circulatory system disorders (Review)
- Authors:
- Ya Qi Gong
- Shuang Wei
- Yuan Yun Wei
- Yong Lin Chen
- Jian Cui
- Yue Qiu Yu
- Xiang Lin
- Hong Xia Yan
- Hui Qin
- Lan Yi
-
Affiliations: Institute of Cytology and Genetics, The Hengyang Key Laboratory of Cellular Stress Biology, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, P.R. China, Institute of Cardiovascular Disease, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, P.R. China, Pediatric Intensive Care Unit, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, P.R. China - Published online on: June 24, 2022 https://doi.org/10.3892/ol.2022.13398
- Article Number: 278
-
Copyright: © Gong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Dang L, Yen K and Attar EC: IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol. 27:599–608. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Montalban-Bravo G and DiNardo CD: The role of IDH mutations in acute myeloid leukemia. Future Oncol. 14:979–993. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma H: Development of novel therapeutics targeting isocitrate dehydrogenase mutations in cancer. Curr Top Med Chem. 18:505–524. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Willander K, Falk IJ, Chaireti R, Paul E, Hermansson M, Gréen H, Lotfi K and Söderkvist P: Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia. Biomark Res. 2:182014. View Article : Google Scholar : PubMed/NCBI | |
|
Xu X, Zhao J, Xu Z, Peng B, Huang Q, Arnold E and Ding J: Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J Biol Chem. 279:33946–33957. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, Chan SM and Swords R: Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. 31:272–281. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Clark O, Yen K and Mellinghoff IK: Molecular pathways: Isocitrate dehydrogenase mutations in cancer. Clin Cancer Res. 22:1837–1842. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liao J, Li Q, Hu Z, Yu W, Zhang K, Ma F, Han Q, Zhang H, Guo J, Hu L, et al: Mitochondrial miR-1285 regulates copper-induced mitochondrial dysfunction and mitophagy by impairing IDH2 in pig jejunal epithelial cells. J Hazard Mater. 422:1268992022. View Article : Google Scholar : PubMed/NCBI | |
|
Lv JW, Song YP, Zhang ZC, Fan YJ, Xu FX, Gao L, Zhang XY, Zhang C, Wang H and Xu DZ: Gestational arsenic exposure induces anxiety-like behaviors in adult offspring by reducing DNA hydroxymethylation in the developing brain. Ecotoxicol Environ Saf. 227:1129012021. View Article : Google Scholar : PubMed/NCBI | |
|
Bergaggio E, Riganti C, Garaffo G, Vitale N, Mereu E, Bandini C, Pellegrino E, Pullano V, Omedè P, Todoerti K, et al: IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. Blood. 133:156–167. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Park JB, Nagar H, Choi S, Jung SB, Kim HW, Kang SK, Lee JW, Lee JH, Park JW, Irani K, et al: IDH2 deficiency impairs mitochondrial function in endothelial cells and endothelium-dependent vasomotor function. Free Radic Biol Med. 94:36–46. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lang F, Jha A, Meuter L, Pacak K and Yang C: Identification of isocitrate dehydrogenase 2 (IDH2) mutation in carotid body paraganglioma. Front Endocrinol (Lausanne). 12:7310962021. View Article : Google Scholar : PubMed/NCBI | |
|
Cairns RA and Mak TW: Oncogenic isocitrate dehydrogenase mutations: Mechanisms, models, and clinical opportunities. Cancer Discov. 3:730–741. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Shi F, He Y, Li J, Tang M, Li Y, Xie L, Zhao L, Hu J, Luo X, Zhou M, et al: Wild-type IDH2 contributes to Epstein-Barr virus-dependent metabolic alterations and tumorigenesis. Mol Metab. 36:1009662020. View Article : Google Scholar : PubMed/NCBI | |
|
Cerchione C, Romano A, Daver N, DiNardo C, Jabbour EJ, Konopleva M, Ravandi-Kashani F, Kadia T, Martelli MP, Isidori A, et al: IDH1/IDH2 inhibition in acute myeloid leukemia. Front Oncol. 11:6393872021. View Article : Google Scholar : PubMed/NCBI | |
|
Stein EM, DiNardo CD, Fathi AT, Pollyea DA, Stone RM, Altman JK, Roboz GJ, Patel MR, Collins R, Flinn IW, et al: Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 133:676–687. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Abou Dalle I and DiNardo CD: The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia. Ther Adv Hematol. 9:163–173. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Rocquain J, Carbuccia N, Trouplin V, Raynaud S, Murati A, Nezri M, Tadrist Z, Olschwang S, Vey N, Birnbaum D, et al: Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer. 10:4012010. View Article : Google Scholar : PubMed/NCBI | |
|
Montoro J, Yerlikaya A, Ali A and Raza A: Improving treatment for myelodysplastic syndromes patients. Curr Treat Options Oncol. 19:662018. View Article : Google Scholar : PubMed/NCBI | |
|
Gelsi-Boyer V, Trouplin V, Roquain J, Adélaïde J, Carbuccia N, Esterni B, Finetti P, Murati A, Arnoulet C, Zerazhi H, et al: ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol. 151:365–375. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Woods BA and Levine RL: The role of mutations in epigenetic regulators in myeloid malignancies. Immunol Rev. 263:22–35. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Molenaar RJ, Thota S, Nagata Y, Patel B, Clemente M, Przychodzen B, Hirsh C, Viny AD, Hosano N, Bleeker FE, et al: Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia. 29:2134–2142. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Buege MJ, DiPippo AJ and DiNardo CD: Evolving treatment strategies for elderly leukemia patients with IDH mutations. Cancers (Basel). 10:1872018. View Article : Google Scholar : PubMed/NCBI | |
|
Amaya ML and Pollyea DA: Targeting the IDH2 pathway in acute myeloid leukemia. Clin Cancer Res. 24:4931–4936. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen TC, Yao CY, Chen YR, Yuan CT, Lin CC, Hsu YC, Chuang PH, Kao CJ, Li YH, Hou HA, et al: Oncogenesis induced by combined Phf6 and Idh2 mutations through increased oncometabolites and impaired DNA repair. Oncogene. 41:1576–1588. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, Jin S, Schenkein DP, Su SM, et al: Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 207:339–344. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chen C, Liu Y, Lu C, Cross JR, Morris JP IV, Shroff AS, Ward PS, Bradner JE, Thompson C and Lowe SW: Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev. 27:1974–1985. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Waitkus MS, Diplas BH and Yan H: Biological role and therapeutic potential of IDH mutations in cancer. Cancer Cell. 34:186–195. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Upadhyay VA, Brunner AM and Fathi AT: Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions. Pharmacol Ther. 177:123–128. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kats LM, Reschke M, Taulli R, Pozdnyakova O, Burgess K, Bhargava P, Straley K, Karnik R, Meissner A, Small D, et al: Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell. 14:329–341. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chotirat S, Thongnoppakhun W, Wanachiwanawin W and Auewarakul CU: Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders. Blood Cells Mol Dis. 54:286–291. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sunthankar KI, Jenkins MT, Cote CH, Patel SB, Welner RS and Ferrell PB: Isocitrate dehydrogenase mutations are associated with altered IL-1β responses in acute myeloid leukemia. Leukemia. 36:923–934. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Venugopal S, Takahashi K, Daver N, Maiti A, Borthakur G, Loghavi S, Short NJ, Ohanian M, Masarova L, Issa G, et al: Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J. 12:102022. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J, Yang J, Wei Q, Weng L, Wu F, Shi Y, Cheng X, Cai X, Hu C and Cao P: Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells. Cell Commun Signal. 18:552020. View Article : Google Scholar : PubMed/NCBI | |
|
Gao M, Zhu H, Fu L, Li Y, Bao X, Fu H, Quan H, Wang L and Lou L: Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants. Cancer Sci. 110:3306–3314. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ma R and Yun CH: Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2. Biochem Biophys Res Commun. 503:2912–2917. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yen K, Travins J, Wang F, David MD, Artin E, Straley K, Padyana A, Gross S, DeLaBarre B, Tobin E, et al: AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discov. 7:478–493. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Quek L, David MD, Kennedy A, Metzner M, Amatangelo M, Shih A, Stoilova B, Quivoron C, Heiblig M, Willekens C, et al: Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nat Med. 24:1167–1177. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kim Y, Jeung HK, Cheong JW, Song J, Bae SH, Lee JI and Min YH: All-trans retinoic acid synergizes with enasidenib to induce differentiation of IDH2-mutant acute myeloid leukemia cells. Yonsei Med J. 61:762–773. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
DiNardo CD, Schuh AC, Stein EM, Montesinos P, Wei AH, de Botton S, Zeidan AM, Fathi AT, Kantarjian HM, Bennett JM, et al: Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): A single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol. 22:1597–1608. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, et al: Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia. Blood. 130:722–731. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, Straley K, Kernytsky A, Liu W, Gliser C, et al: Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 340:622–626. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J, Yang J, Sun X, Wang Z, Cheng X, Lu W, Cai X, Hu C, Shen X and Cao P: Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q. Sci Rep. 7:164582017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Zhang Z, Li Y, Sun L, Peng D, Du D, Zhang X, Han L, Zhao L, Lu L, et al: Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China. Acta Pharm Sin B. 11:1526–1540. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Aref S, Kamel Areida el S, Abdel Aaal MF, Adam OM, El-Ghonemy MS, El-Baiomy MA and Zeid TA: Prevalence and clinical effect of IDH1 and IDH2 mutations among cytogenetically normal acute myeloid leukemia patients. Clin Lymphoma Myeloma Leuk. 15:550–555. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Middeke JM, Metzeler KH, Röllig C, Krämer M, Eckardt JN, Stasik S, Greif PA, Spiekermann K, Rothenberg-Thurley M, Krug U, et al: Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: Results from a large multicenter study. Blood Adv. 6:1394–1405. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, Berthon C, Adès L, Fenaux P, Beyne-Rauzy O, et al: Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 31:2428–2436. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Willekens C, Rahme R, Duchmann M, Vidal V, Saada V, Broutin S, Delahousse J, Renneville A, Marceau A, Clappier E, et al: Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: A French retrospective multicenter study. Leuk Lymphoma. 62:438–445. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Hosono N: Genetic abnormalities and pathophysiology of MDS. Int J Clin Oncol. 24:885–892. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Lin J, Yao DM, Qian J, Chen Q, Qian W, Li Y, Yang J, Wang CZ, Chai HY, Qian Z, et al: IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol. 91:519–525. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, Hunault-Berger M, Slama B, Vey N, Lacombe C, et al: Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia. 24:1094–1096. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lin CC, Hou HA, Chou WC, Kuo YY, Liu CY, Chen CY, Lai YJ, Tseng MH, Huang CF, Chiang YC, et al: IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution. Am J Hematol. 89:137–144. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lin P, Luo Y, Zhu S, Maggio D, Yang H, Hu C, Wang J, Zhang H, Ren Y, Zhou X, et al: Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes. J Cancer Res Clin Oncol. 144:1037–1047. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kharfan-Dabaja MA, Komrokji RS, Zhang Q, Kumar A, Tsalatsanis A, Perkins J, Nishihori T, Field T, Al Ali N, Mishra A, et al: TP53 and IDH2 somatic mutations are associated with inferior overall survival after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 17:753–758. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Stein EM, Fathi AT, DiNardo CD, Pollyea DA, Roboz GJ, Collins R, Sekeres MA, Stone RM, Attar EC, Frattini MG, et al: Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: A phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 7:e309–e319. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 89:2079–2088. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Turkalp Z, Karamchandani J and Das S: IDH mutation in glioma: New insights and promises for the future. JAMA Neurol. 71:1319–1325. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Li JJ, Li R, Wang W, Zhang B, Song X, Zhang C, Gao Y, Liao Q, He Y, You S, et al: IDH2 is a novel diagnostic and prognostic serum biomarker for non-small-cell lung cancer. Mol Oncol. 12:602–610. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chiang S, Weigelt B, Wen HC, Pareja F, Raghavendra A, Martelotto LG, Burke KA, Basili T, Li A, Geyer FC, et al: IDH2 mutations define a unique subtype of breast cancer with altered nuclear polarity. Cancer Res. 76:7118–7129. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Steinhilber J, Mederake M, Bonzheim I, Serinsöz-Linke E, Müller I, Fallier-Becker P, Lemonnier F, Gaulard P, Fend F and Quintanilla-Martinez L: The pathological features of angioimmunoblastic T-cell lymphomas with IDH2R172 mutations. Mod Pathol. 32:1123–1134. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu GG, Nafa K, Agaram N, Zehir A, Benayed R, Sadowska J, Borsu L, Kelly C, Tap WD, Fabbri N, et al: Genomic profiling identifies association of IDH1/IDH2 mutation with longer relapse-free and metastasis-free survival in high-grade chondrosarcoma. Clin Cancer Res. 26:419–427. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Libera L, Ottini G, Sahnane N, Pettenon F, Turri-Zanoni M, Lambertoni A, Chiaravalli AM, Leone F, Battaglia P, Castelnuovo P, et al: Methylation drivers and prognostic implications in sinonasal poorly differentiated carcinomas. Cancers (Basel). 13:50302021. View Article : Google Scholar : PubMed/NCBI | |
|
Miller JJ, Shih HA, Andronesi OC and Cahill DP: Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications. Cancer. 123:4535–4546. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Qi S, Yu L, Li H, Ou Y, Qiu X, Ding Y, Han H and Zhang X: Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncol Lett. 7:1895–1902. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Picca A, Berzero G, Di Stefano AL and Sanson M: The clinical use of IDH1 and IDH2 mutations in gliomas. Expert Rev Mol Diagn. 18:1041–1051. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Gusyatiner O and Hegi ME: Glioma epigenetics: From subclassification to novel treatment options. Semin Cancer Biol. 51:50–58. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ludwig N, Rao A, Sandlesh P, Yerneni SS, Swain AD, Bullock KM, Hansen KM, Zhang X, Jaman E, Allen J, et al: Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles. Neuro Oncol. 24:197–209. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Phan K, Ng W, Lu VM, McDonald KL, Fairhall J, Reddy R and Wilson P: Association between IDH1 and IDH2 mutations and preoperative seizures in patients with low-grade versus high-grade glioma: A systematic review and meta-analysis. World Neurosurg. 111:e539–e545. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen R, Ravindra VM, Cohen AL, Jensen RL, Salzman KL, Prescot AP and Colman H: Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Neurosurg Focus. 38:E22015. View Article : Google Scholar : PubMed/NCBI | |
|
Thirumal Kumar D, Jerushah Emerald L, George Priya Doss C, Sneha P, Siva R, Charles Emmanuel Jebaraj W and Zayed H: Computational approach to unravel the impact of missense mutations of proteins (D2HGDH and IDH2) causing D-2-hydroxyglutaric aciduria 2. Metab Brain Dis. 33:1699–1710. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kim H, Kim SH, Cha H, Kim SR, Lee JH and Park JW: IDH2 deficiency promotes mitochondrial dysfunction and dopaminergic neurotoxicity: Implications for Parkinson's disease. Free Radic Res. 50:853–860. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Lu J, He Y, Wu Y, Wu Y, Song X, Jiang Y, Tang M, Weng X, Yi W, et al: A new functional IDH2 genetic variant is associated with the risk of lung cancer. Mol Carcinog. 56:1082–1087. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, He Y, Tan Z, Lu J, Li L, Song X, Shi F, Xie L, You S, Luo X, et al: Wild-type IDH2 promotes the Warburg effect and tumor growth through HIF1α in lung cancer. Theranostics. 8:4050–4061. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Park JH, Ku HJ, Lee JH and Park JW: Idh2 deficiency exacerbates acrolein-induced lung injury through mitochondrial redox environment deterioration. Oxid Med Cell Longev. 2017:15951032017. View Article : Google Scholar : PubMed/NCBI | |
|
Park JH, Ku HJ, Lee JH and Park JW: Disruption of IDH2 attenuates lipopolysaccharide-induced inflammation and lung injury in an α-ketoglutarate-dependent manner. Biochem Biophys Res Commun. 503:798–802. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Holst JM, Enemark MB, Pedersen MB, Lauridsen KL, Hybel TE, Clausen MR, Frederiksen H, Møller MB, Nørgaard P, Plesner TL, et al: Proteomic profiling differentiates lymphoma patients with and without concurrent myeloproliferative neoplasia. Cancers (Basel). 13:55262021. View Article : Google Scholar : PubMed/NCBI | |
|
Lemonnier F, Cairns RA, Inoue S, Li WY, Dupuy A, Broutin S, Martin N, Fataccioli V, Pelletier R, Wakeham A, et al: The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. Proc Natl Acad Sci USA. 113:15084–15089. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald A, Gascoyne RD, Wu X, Wang J, Muhammad Z, et al: IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood. 126:1741–1752. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Churchill H, Naina H, Boriack R, Rakheja D and Chen W: Discordant intracellular and plasma D-2-hydroxyglutarate levels in a patient with IDH2 mutated angioimmunoblastic T-cell lymphoma. Int J Clin Exp Pathol. 8:11753–11759. 2015.PubMed/NCBI | |
|
Dupuy A, Lemonnier F, Fataccioli V, Martin-Garcia N, Robe C, Pelletier R, Poullot E, Moktefi A, Mokhtari K, Rousselet MC, et al: Multiple ways to detect IDH2 mutations in angioimmunoblastic T-cell lymphoma from immunohistochemistry to next-generation sequencing. J Mol Diagn. 20:677–685. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ye Y, Ding N, Mi L, Shi Y, Liu W, Song Y, Shu S and Zhu J: Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas. Exp Hematol Oncol. 10:92021. View Article : Google Scholar : PubMed/NCBI | |
|
Pareja F, da Silva EM, Frosina D, Geyer FC, Lozada JR, Basili T, Da Cruz Paula A, Zhong E, Derakhshan F, D'Alfonso T, et al: Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: Applications in the diagnosis of tall cell carcinoma with reverse polarity. Mod Pathol. 33:1056–1064. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Aljohani AI, Toss MS, Kurozumi S, Joseph C, Aleskandarany MA, Miligy IM, Ansari RE, Mongan NP, Ellis IO, Green AR and Rakha EA: The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer. Breast Cancer Res Treat. 179:79–90. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Agarwal E, Bertolini I, Ghosh JC, Seo JH and Altieri DC: IDH2 reprograms mitochondrial dynamics in cancer through a HIF-1α-regulated pseudohypoxic state. FASEB J. 33:13398–13411. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Jo VY, Chau NG, Hornick JL, Krane JF and Sholl LM: Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma. Mod Pathol. 30:650–659. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Dogan S, Chute DJ, Xu B, Ptashkin RN, Chandramohan R, Casanova-Murphy J, Nafa K, Bishop JA, Chiosea SI, Stelow EB, et al: Frequent IDH2 R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas. J Pathol. 242:400–408. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Riobello C, López-Hernández A, Cabal VN, García-Marín R, Suárez-Fernández L, Sánchez-Fernández P, Vivanco B, Blanco V, López F, Franchi A, et al: IDH2 mutation analysis in undifferentiated and poorly differentiated sinonasal carcinomas for diagnosis and clinical management. Am J Surg Pathol. 44:396–405. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kim YR, Kim KH, Lee S, Oh SK, Park JW, Lee KY, Baek JI and Kim UK: Expression patterns of members of the isocitrate dehydrogenase gene family in murine inner ear. Biotech Histochem. 92:536–544. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
White K, Kim MJ, Han C, Park HJ, Ding D, Boyd K, Walker L, Linser P, Meneses Z, Slade C, et al: Loss of IDH2 accelerates age-related hearing loss in male mice. Sci Rep. 8:50392018. View Article : Google Scholar : PubMed/NCBI | |
|
Ku HJ, Park JH, Kim SH and Park JW: Isocitrate dehydrogenase 2 deficiency exacerbates dermis damage by ultraviolet-B via ΔNp63 downregulation. Biochim Biophys Acta Mol Basis Dis. 1864:1138–1147. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SH and Park JW: IDH2 deficiency impairs cutaneous wound healing via ROS-dependent apoptosis. Biochim Biophys Acta Mol Basis Dis. 1865:1655232019. View Article : Google Scholar : PubMed/NCBI | |
|
Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, Xu W, Tan L, Hu Y, Zhan Q, et al: Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell. 150:1135–1146. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lv Q, Xing S, Li Z, Li J, Gong P, Xu X, Chang L, Jin X, Gao F, Li W, et al: Altered expression levels of IDH2 are involved in the development of colon cancer. Exp Ther Med. 4:801–806. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Teicher BA, Linehan WM and Helman LJ: Targeting cancer metabolism. Clin Cancer Res. 18:5537–5545. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Park JH, Ku HJ, Lee JH and Park JW: IDH2 deficiency accelerates skin pigmentation in mice via enhancing melanogenesis. Redox Biol. 17:16–24. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Z, Gan L, Zhang T, Ren Q and Sun C: Melatonin alleviates adipose inflammation through elevating α-ketoglutarate and diverting adipose-derived exosomes to macrophages in mice. J Pineal Res. 64:e124552018. View Article : Google Scholar | |
|
Gong F, Gao L and Ding T: IDH2 protects against nonalcoholic steatohepatitis by alleviating dyslipidemia regulated by oxidative stress. Biochem Biophys Res Commun. 514:593–600. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Zhuo S, Xu W, Chen X, Huang D, Sun X and Cheng Y: Isocitrate dehydrogenase 2 contributes to radiation resistance of oesophageal squamous cell carcinoma via regulating mitochondrial function and ROS/pAKT signalling. Br J Cancer. 123:126–136. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lee SJ, Cha H, Lee S, Kim H, Ku HJ, Kim SH, Park JH, Lee JH, Park KM and Park JW: Idh2 deficiency accelerates renal dysfunction in aged mice. Biochem Biophys Res Commun. 493:34–39. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lee SH, Jo SH, Lee SM, Koh HJ, Song H, Park JW, Lee WH and Huh TL: Role of NADP+-dependent isocitrate dehydrogenase (NADP+-ICDH) on cellular defence against oxidative injury by gamma-rays. Int J Radiat Biol. 80:635–642. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Lee JH, Go Y, Kim DY, Lee SH, Kim OH, Jeon YH, Kwon TK, Bae JH, Song DK, Rhyu IJ, et al: Isocitrate dehydrogenase 2 protects mice from high-fat diet-induced metabolic stress by limiting oxidative damage to the mitochondria from brown adipose tissue. Exp Mol Med. 52:238–252. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lee JH, Kim SY, Kil IS and Park JW: Regulation of ionizing radiation-induced apoptosis by mitochondrial NADP+-dependent isocitrate dehydrogenase. J Biol Chem. 282:13385–13394. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SY, Yoo YH and Park JW: Silencing of mitochondrial NADP(+)-dependent isocitrate dehydrogenase gene enhances glioma radiosensitivity. Biochem Biophys Res Commun. 433:260–265. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Li S, Chou AP, Chen W, Chen R, Deng Y, Phillips HS, Selfridge J, Zurayk M, Lou JJ, Everson RG, et al: Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro Oncol. 15:57–68. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, et al: IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the European organization for research and treatment of cancer brain tumor group. Clin Cancer Res. 16:1597–1604. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bleeker FE, Atai NA, Lamba S, Jonker A, Rijkeboer D, Bosch KS, Tigchelaar W, Troost D, Vandertop WP, Bardelli A and Van Noorden CJ: The prognostic IDH1 (R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol. 119:487–494. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Cho HJ, Cho HY, Park JW, Kwon OS, Lee HS, Huh TL and Kang BS: NADP+-dependent cytosolic isocitrate dehydrogenase provides NADPH in the presence of cadmium due to the moderate chelating effect of glutathione. J Biol Inorg Chem. 23:849–860. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao CB, Shi L, Pu HH and Zhang QY: The promoting effect of radiation on glucose metabolism in breast cancer cells under the treatment of cobalt chloride. Pathol Oncol Res. 23:47–53. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Oliveira P, Barboza LGA, Branco V, Figueiredo N, Carvalho C and Guilhermino L: Effects of microplastics and mercury in the freshwater bivalve corbicula fluminea (Müller, 1774): Filtration rate, biochemical biomarkers and mercury bioconcentration. Ecotoxicol Environ Saf. 164:155–163. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kil IS, Shin SW, Yeo HS, Lee YS and Park JW: Mitochondrial NADP+-dependent isocitrate dehydrogenase protects cadmium-induced apoptosis. Mol Pharmacol. 70:1053–1061. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Li C, Xu Y, Li L, Yang X and Wang Y: Acid stress induces cross-protection for cadmium tolerance of multi-stress-tolerant Pichia kudriavzevii by regulating cadmium transport and antioxidant defense system. J Hazard Mater. 366:151–159. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
da Silva Fonseca J, de Barros Marangoni LF, Marques JA and Bianchini A: Energy metabolism enzymes inhibition by the combined effects of increasing temperature and copper exposure in the coral mussismilia harttii. Chemosphere. 236:1244202019. View Article : Google Scholar : PubMed/NCBI | |
|
Pan JH, Kim HS, Beane KE, Montalbano AM, Lee JH, Kim YJ, Kim JH, Kong BC, Kim S, Park JW, et al: IDH2 deficiency aggravates fructose-induced NAFLD by modulating hepatic fatty acid metabolism and activating inflammatory signaling in female mice. Nutrients. 10:6792018. View Article : Google Scholar : PubMed/NCBI | |
|
Chae U, Park JW, Lee SR, Lee HJ, Lee HS and Lee DS: Reactive oxygen species-mediated senescence is accelerated by inhibiting Cdk2 in Idh2-deficient conditions. Aging (Albany NY). 11:7242–7256. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Y, Liu L, Nakamura A, Someya S, Miyakawa T and Tanokura M: Studies on the regulatory mechanism of isocitrate dehydrogenase 2 using acetylation mimics. Sci Rep. 7:97852017. View Article : Google Scholar : PubMed/NCBI | |
|
Yu W, Dittenhafer-Reed KE and Denu JM: SIRT3 protein deacetylates isocitrate dehydrogenase 2 (IDH2) and regulates mitochondrial redox status. J Biol Chem. 287:14078–14086. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zou X, Zhu Y, Park SH, Liu G, O'Brien J, Jiang H and Gius D: SIRT3-mediated dimerization of IDH2 directs cancer cell metabolism and tumor growth. Cancer Res. 77:3990–3999. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Smolková K, Špačková J, Gotvaldová K, Dvořák A, Křenková A, Hubálek M, Holendová B, Vítek L and Ježek P: SIRT3 and GCN5L regulation of NADP+- and NADPH-driven reactions of mitochondrial isocitrate dehydrogenase IDH2. Sci Rep. 10:86772020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang T, Zhang F, Peng W, Wang L, Zhang J, Dong W, Tian X, Ye C, Li Y and Gong Y: Overexpression of NMNAT3 improves mitochondrial function and enhances antioxidative stress capacity of bone marrow mesenchymal stem cells via the NAD+-Sirt3 pathway. Biosci Rep. 42:BSR202110052022. View Article : Google Scholar : PubMed/NCBI | |
|
Yu Y, Chen Y, Liu K, Cheng J and Tu J: SUMOylation enhances the activity of IDH2 under oxidative stress. Biochem Biophys Res Commun. 532:591–597. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ogawara Y, Katsumoto T, Aikawa Y, Shima Y, Kagiyama Y, Soga T, Matsunaga H, Seki T, Araki K and Kitabayashi I: IDH2 and NPM1 mutations cooperate to activate Hoxa9/Meis1 and hypoxia pathways in acute myeloid Leukemia. Cancer Res. 75:2005–2016. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Leonardi R, Subramanian C, Jackowski S and Rock CO: Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation. J Biol Chem. 287:14615–14620. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kim H, Lee JH and Park JW: Down-regulation of IDH2 sensitizes cancer cells to erastin-induced ferroptosis. Biochem Biophys Res Commun. 525:366–371. 2020. View Article : Google Scholar : PubMed/NCBI |
